BOSTON, July 10 /PRNewswire/ -- Many researchers believe the key to combating cancer in the 21st century will be through improved prevention, screening and early detection of the disease. And surely they are correct as when colon cancer is detected early, the cure rate is now 95 percent. Yet, cancer research is the building block of understanding and treating this wide-spread disease.
The 8th Annual Anti-Cancer Drug Discover & Development Summit, to be held on July 17-18, 2006, will include the most prominent experts in the field of cancer research as well as the latest anti-cancer research on: 1) Targeted Therapeutics, 2) Antibody Derived Targets & Biologics, and 3) Angiogenesis.
Highlighted research programs include the following: -- Targeting VEGF Pathway with mAb’s and Small Molecules -- EGF Pathway Inhibitors (Erlotinib and Cetuximab) -- Emerging Approaches to Target the c-Met/ HGF Axis -- Selective and Multi-Targeted Kinase Inhibitors -- Novel Biologicals (CD20, CTLA4, Angiopoietins, PSCA, SDF and Eph) -- Emerging Data on Inhibitors of Mek, Hedgehog, CDK and HDAC
Complete list of participating companies and institutions includes: Agensys, Amgen, Arqule, Array Biopharma, Astrazeneca, Chemokine Therapeutics, Compound Therapeutics, Curagen, Curis, Dana-Farber Cancer Institute, Exelixis, Genentech, Genmab A/S, Harvard University, Hoffmann-La Roche, Immunogen, Ludwig Center for Cancer Research, MD Anderson Cancer Center, Medarex, Medimmune, MIT, OSI Pharmaceuticals, Pfizer, Sunesis, Sherris Pharma Partners, University of Texas and Whitehead Institute.
To receive the full agenda in PDF, to register, or for information on becoming a media partner, please contact Amy Yueh of Strategic Research Institute at ayueh@srinstitute.com or 212-967-0095, x258. The conference website is http://www.srinstitute.com/cancer .
Strategic Research Institute http://www.srinstitute.com
Strategic Research Institute
CONTACT: Amy Yueh of Strategic Research Institute, ayueh@srinstitute.com,+1-212-967-0095, x258
